GTCR to Acquire Zentiva for EUR 4.1bn in Strategic Platform Deal to Drive European Generics Consolidation

In a landmark healthcare deal, U.S. private equity firm GTCR has reached an agreement to acquire Czech-based generics pharmaceutical company Zentiva from fellow financial investor Advent International. The transaction, valued at EUR 4.1bn, is expected to close in early 2026, pending regulatory approvals, and marks one of the largest private equity buyouts in Europe’s pharma sector this year.

Headquartered in Prague, Zentiva develops and manufactures affordable, high-quality medicines for over 100 million people across more than 30 countries, with a strong presence in Central and Eastern Europe (CEE). It operates four wholly owned manufacturing facilities in the Czech Republic, Romania (two sites), and India, and employs more than 5,000 people globally. The company’s flagship European sites run entirely on renewable energy, highlighting its sustainability credentials.

GTCR, a Chicago-based firm with over USD 50bn in assets under management, plans to leverage Zentiva as a strategic platform for expansion across the fragmented European generics, consumer health, and biosimilars markets.

The acquisition is GTCR’s latest push into essential healthcare infrastructure and underlines growing private equity interest in Europe’s pharmaceutical sector. The announcement comes just days after rival private equity group CapVest acquired a majority stake in Germany's Stada from Bain Capital and Cinven — a deal estimated at around EUR 10bn. Like Zentiva, Stada also has a strong presence in emerging markets, making the two back-to-back deals a signal of intensifying competition for scale-ready pharma platforms.

Zentiva’s rise as a leading standalone generics company is rooted in its 2018 carve-out from Sanofi, when Advent International acquired the business for EUR 1.9bn. At the time, Sanofi viewed its European generics division as non-core. Since then, Zentiva has more than doubled its revenue and EBITDA, expanded its R&D capabilities, and scaled production — becoming a key player in Europe’s generics ecosystem.

For GTCR, the acquisition represents a classic buy-and-build strategy, with a strong focus on bolt-on acquisitions, product innovation, and platform synergies. With Europe’s generics and OTC drug market still highly fragmented, GTCR aims to use Zentiva to consolidate regional players and enhance its position in consumer health and biosimilars — two of the sector’s most dynamic growth areas.

The deal underscores a broader trend of private equity investment in CEE’s healthcare sector and further positions GTCR at the heart of Europe’s evolving pharmaceutical landscape.